10th Annual Oncology Innovation Forum

We are pleased to announce that the 10th Annual Oncology Innovation Forum (Sachs_OIF) will take place at the Waldorf Astoria Chicago Hotel on the 31st of May 2024, at the beginning of the ASCO meeting. The Virtual Week will follow from the 12th to 14th of June.

The 10th Annual OIF is an established networking opportunity for senior biotech executives to meet Pharma Licensing teams and financial and corporate investors and their advisers. Meetings take place alongside a stimulating program focusing on the latest trends in pharma-biotech dealmaking, the latest innovation in IO targets and modalities. There is also an ASCO forecast panel with industry analysts sharing their views on what to expect. This will be available on demand for the virtual audience the week after ASCO. Additionally, there will be pre-arranged in-person and virtual meetings, live and on-demand company showcases, and a reception.

The event brings together leaders from cancer research institutes, patient advocacy groups, pharma, biotech, and Wall Street, to facilitate partnering, funding and investment. We anticipate around 250 delegates and 20+ company presentations by established and emerging companies with part of the audience participating virtually. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand. Recorded sessions will also be added on demand on the events portal during the virtual week.

The programme will consist of:

Friday, 31st of May (Central Daylight Time (CDT) zone):

• BioPharma Dealmakers Roundtable
• New Endpoints for Early-Stage Oncology Companies Panel
• Investing in NextGen ADCs Panel
• Advanced Immunotherapies Panel: Cell Therapies & Cancer Vaccines
• New Methods of Therapeutic Delivery for Oncology Panel
• New Hubs for Innovation Panel
• ASCO Forecast Discussion

Networking Reception – 31st of May
In-Person Meetings – 31st of May
Virtual Meetings via Online Meeting System – 12th – 14th of June (Eastern Daylight Time (EDT) zone)

Confirmed Speakers & Chairs Include:

• Andreas Pahl, CEO, Heidelberg Pharma AG
• Benjamin Burnett, Equity Research Analyst, Stifel
• Brad Loncar, Founder, BiotechTV
• Colette Lipp, Director, Global BD Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany
• David G. Benathan, VP, BD&L Partnering Head Oncology, Novartis AG
• Deborah Rathjen, Managing Director & CEO, Carina Biotech Limited
• Devang Bhuva, SVP, Corporate Development & Alliance Management, Gilead Sciences, Inc.
• Evonne Sepsis, Managing Director, ESC Advisors
• Gregor Fachinger, VP, Head of Oncology & Immuno-Oncology Business Development, Merck KGaA, Darmstadt, Germany
• Jacob Plieth, Senior Reporter, ApexOnco
• James Barlow, President & CEO, ImmunoGenesis, Inc.
• Jay Olson, Managing Director & Senior Analyst, Oppenheimer & Co. Inc.
• Jean-Pierre Latere, CEO, EsoBiotec
• Jeffrey Bockman, EVP Expert Advisor, Oncology, Lumanity Head, Oncology Center of Excellence, Lumanity
• Joel Sandler, Associate Partner, Ipsos Healthcare Advisory Service
• John DeYoung, VP, Worldwide Business Development, Pfizer, Inc.
• John Flavin, Founder & CEO, Portal Innovations, LLC
• Jun Xu, Executive Director – Therapy Acceleration Program Lead, The Leukemia & Lymphoma Society
• Kaveri Pohlman, Director, Biotechnology Equity Research, BTIG, LLC
• Margarita Chavez, Venture Partner, Wellington Partners
• Matthew Price, Co-Founder, EVP & Chief Operating Officer, Promontory Therapeutics Inc.
• Maurits Geerlings, President & CEO, NanoCell Therapeutics, Inc.
• Max Nisen, Equity Research Analyst, Pharma & Biotech, Bloomberg Intelligence
• Michael Kingston, Managing Director & Head of North America Life Sciences, Lazard Ltd.
• Michael Rice, Expert Advisor, SVP, Cell & Gene Therapy, Lumanity
• Michael Salgaller, Supervisor Specialist, National Institutes of Health (NIH)
• Michal Preminger, Regional Head, Johnson & Johnson Innovation East North America, Johnson & Johnson Innovation LLC
• Nadim Ahmed, President & CEO, Cullinan Therapeutics, Inc.
• Nicole Fay, Director of Pharmacology, Nutcracker Therapeutics, Inc.
• Niels Emmerich, VP, Search & Evaluation & Global Alliances, AbbVie, Inc.
• Niranjan Sardesai, Founder, President & CEO, Geneos Therapeutics, Inc.
• Omari Wise, Vice President Business Development, Amgen, Inc.
• Paul Rennert, CEO, Aleta Biotherapeutics
• Pete DeMuth, Chief Scientific Officer, Elicio Therapeutics, Inc.
• Peter Sandor, EVP Head of Corporate Strategy, Astellas Pharma, Inc.
• Polly Brown, VP, Head of Business Development, Oncology R&D, AstraZeneca
• Raven Lin, Co-Founder & CEO, Pilatus Biosciences SA
• Sath Nirmalananthan, Chief Financial Officer, Scancell Holdings PLC
• Sharon Chan, VP JLABS Asia Pacific, Johnson & Johnson
• Susie Harborth, Chief Business Officer, Breakthrough Properties
• Uciane Scarlett, Principal Venture Capitalist, MPM BioImpact
• Upendra Marathi, CEO, 7 Hills Pharma Inc.
• Vivek Abraham, Director, Oncology Search & Evaluation, AbbVie, Inc.
• Xavier Avat, Chief Business Officer, Moffitt Cancer Center
• Yuval Cohen, CEO, Corbus Pharmaceuticals Holdings, Inc.

Complimentary passes are provided for qualified institutional (buy/sell-side), private equity and venture investors. The number of passes is limited, and priority is given to regular participants, however the organiser has the discretion to reject registrations. Other participants may consider purchasing access, which includes in-person or virtual participation, with different options to showcase your company.

The Online Meeting System will open on the 17th of May for uploading profiles and sending meeting invites. The in-person meetings will be taking place on the 31st of May, while virtual meetings will take place on the 12th – 14th of June. For the virtual meetings, the system will allow you to have a secure audio/video call, as well as an option to present slides using a screen share function and we will have a dedicated room for in-person meetings.

Gain additional exposure to high-level decision makers by presenting at the forum, which offers excellent opportunities to showcase your company’s investment and partnering offering. This typically includes technology and financial highlights. This adds to the news flow from the forum and generates greater interest in meetings from other delegates.

Presentations are a popular and useful way to gain additional exposure with potential investors and pharma partners, which make up over half the audience. We are pleased to announce that once again we will have 20-minute and 10-minute presentations taking place in-person at the dedicated presenting tracks. Here you will be able to showcase your company in front of investors attending the physical event. The recording will be added to your company’s profile during the virtual week, which will be available on demand for registered participants until the event portal closes.

For those who cannot present in-person, but are still interested to showcase their company, there is an option to purchase either a 20 or 10 minute presentation, which will be pre-recorded in advance and available to all registered attendees on the events portal. Start-up companies may also purchase a 5-minute pre-recorded showcase instead.

The Sachs Team can assist with the pre-recording of the presentation, or you can upload a video you already have. Interested viewers will be able to message or request a meeting with you using the Online Meeting System